<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Illness and Diseases &#187; Diseases</title>
	<atom:link href="http://www.diseases-illness.com/diseases/feed" rel="self" type="application/rss+xml" />
	<link>http://www.diseases-illness.com</link>
	<description></description>
	<lastBuildDate>Fri, 26 Mar 2021 06:46:54 +0000</lastBuildDate>
	<language>en-US</language>
		<sy:updatePeriod>hourly</sy:updatePeriod>
		<sy:updateFrequency>1</sy:updateFrequency>
	<generator>https://wordpress.org/?v=4.0.38</generator>
	<item>
		<title>The Bonferroni method</title>
		<link>http://www.diseases-illness.com/the-bonferroni-method-in-canadian-pharmacy.html</link>
		<comments>http://www.diseases-illness.com/the-bonferroni-method-in-canadian-pharmacy.html#comments</comments>
		<pubDate>Tue, 11 Nov 2014 00:17:00 +0000</pubDate>
		<dc:creator><![CDATA[Dan Frost]]></dc:creator>
				<category><![CDATA[Diseases]]></category>

		<guid isPermaLink="false">http://www.diseases-illness.com/in-hospital-mortality-and-need-for-mv-at-any-point-during-the-hospitalization-served-as-co-primary-end-points.html</guid>
		<description><![CDATA[The designation into risk classes III, IV, and V are based on the whether the patient has one, two, or three of the central risk factors, respectively. We defined the occurrence of altered mental status as an initial Glasgow Coma score &#60; 14 or a designation by the physician of disorientation, stupor, or coma. End Points and Sensitivity Analyses In-hospital [&#8230;]]]></description>
				<content:encoded><![CDATA[<p style="text-align: justify;">T<strong>he designation into risk classes III, IV, and V are based on the whether the patient has one, two, or three of the central risk factors, respectively.</strong> We defined the occurrence of altered mental status as an initial Glasgow Coma score &lt; 14 or a designation by the physician of disorientation, stupor, or coma.</p>
<p style="text-align: justify;"><strong>End Points and Sensitivity Analyses</strong></p>
<p style="text-align: justify;">In-hospital mortality and need for MV at any point during the hospitalization served as co-primary end points. We further explored LOS and hospital costs relative to the BAP-65 score. Costs were computed by converting hospital charges by institution-specific cost-to-charge ratios obtained from the Centers for Medicare and Medicaid Services.</p>
<p style="text-align: justify;"><strong>Because both the timing of death and issues related to limitations in the intensity of care may affect resource use and LOS in hospitalized patients, we conducted a sensitivity analysis examining LOS and costs among only hospital survivors.</strong> By completing an evaluation of resource use in only survivors we aimed to limit confounding due to these concerns. In addition, we validated the BAP-65 in patients with principal diagnosis of AECOPD only, using the same definition as the one used for the original BAP-65 study.</p>
<p style="text-align: justify;"><span id="result_box" class="" lang="en"><span class="hps">Stay tuned for updates</span> <span class="hps">and subscribe to</span> <span class="hps">our <a title="canadian health and care mall" href="https://twitter.com/healthcare_mall">twitter</a>. Canadian health care news online)!</span></span></p>
<h3 style="text-align: justify;">Statistical Analysis</h3>
<p style="text-align: justify;">Categorical variables were compared with a x<sup>2</sup> test, and continuous variables were compared via analysis of variance. The Cochrane-Armitage trending statistic was used to assess whether the risk score could differentiate low-risk from high-risk patients in a fashion reflecting a graded response based on the level of risk present for mortality and MV use. <strong>For contrast test, we used x<sup>2</sup> test for categorical variable and Welch t test for continuous variables.</strong> We used the Bonferroni method to adjust for four follow-up tests of differences in each of the four end points from one BAP-65 class to the next. A P value of &lt; .0125 was considered statistically significant and all tests were two-sided. We assessed the predictive ability of the BAP-65 for the primary end points using the area under the receiver operating characteristic curve (AUROC). We constructed 95% CIs for the AUROC using 1,000 bootstrap iterations. We assessed sensitivity, specificity, and positive and negative predictive values of the BAP-65 for the primary end points.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.diseases-illness.com/the-bonferroni-method-in-canadian-pharmacy.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Hypertension, congestive heart failure, and diabetes mellitus</title>
		<link>http://www.diseases-illness.com/the-most-common-comorbidities-were-hypertension-congestive-heart-failure-and-diabetes-mellitus.html</link>
		<comments>http://www.diseases-illness.com/the-most-common-comorbidities-were-hypertension-congestive-heart-failure-and-diabetes-mellitus.html#comments</comments>
		<pubDate>Mon, 13 Oct 2014 00:18:25 +0000</pubDate>
		<dc:creator><![CDATA[Dan Frost]]></dc:creator>
				<category><![CDATA[Diabetes]]></category>
		<category><![CDATA[Diseases]]></category>

		<guid isPermaLink="false">http://www.diseases-illness.com/the-most-common-comorbidities-were-hypertension-congestive-heart-failure-and-diabetes-mellitus.html</guid>
		<description><![CDATA[Results The final cohort included 34,669 subjects, of whom 80.6% had a principal diagnosis of AECOPD and the remainder had acute respiratory failure noted as the principal diagnosis along with COPD as a secondary diagnosis. As shown in Table 1, the median age was 72 years and 46.4% were men. The most common comorbidities were hypertension, congestive heart failure, and diabetes [&#8230;]]]></description>
				<content:encoded><![CDATA[<p style="text-align: justify;">Results</p>
<p style="text-align: justify;"><strong>The final cohort included 34,669 subjects, of whom 80.6% had a principal diagnosis of AECOPD and the remainder had acute respiratory failure noted as the principal diagnosis along with COPD as a secondary diagnosis.</strong> As shown in Table 1, the median age was 72 years and 46.4% were men. The most common comorbidities were hypertension, congestive heart failure, and diabetes mellitus.</p>
<p style="text-align: justify;">Approximately 4% of patients died while in the hospital, and MV was required at any point in 9.2%. We observed the pooled end point of either in-hospital mortality or ever needing MV in 11.2% of the population. Mortality rates increased with escalating BAP class (Fig 1A) (Cochran-Armitage trend test z = —38.48, P &lt; .001). Similarly, the use of MV (Fig 1B) escalated in a stepwise fashion as the score increased (Cochran-Armitage trend test z = —58.89, P&lt; .001). Follow-up x<sup>2</sup> tests and P values of differences in mortality and MV use from one class to the next can be found in Figures 1A and 1B, respectively.</p>
<p style="text-align: justify;">Figure 2 demonstrates the ROC curves for the BAP-65 system at predicting either death and/or application of MV. For the pooled end point of MV or mortality, the AUROC was 0.79 (95% CI, 0.78-0.80). The BAP-65 performed similarly at assessing each component of the pooled end point. For mortality, the AUROC equaled 0.77 (95% CI, 0.76-0.78), whereas it was 0.78 (95% CI, 0.78-0.79) for MV use.</p>
<p style="text-align: justify;">For the pooled end point, the cutoff point of class &gt; II, &gt; III, &gt; IV, or V corresponded to sensitivity ranging from 0.97 to 0.12, specificity ranging from 0.18 to 0.99, a positive predictive value ranging from 0.13 to 0.64, and a negative predictive value ranging from 0.98 to 0.90, respectively (Table 2).</p>
<p style="text-align: justify;">We observed a median LOS of 4 days (interquartile range [IQR], 3-7 days) with associated median costs of $5,357 (IQR, $3,479-$8,635). Among patients meeting no BAP-65 criteria, the median LOS was only 3 days (IQR, 2-5 days). The median LOS more than doubled (median of 7 days; IQR, 3-11 days) in the most severely ill subjects who had all BAP-65 conditions.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.diseases-illness.com/the-most-common-comorbidities-were-hypertension-congestive-heart-failure-and-diabetes-mellitus.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Diagnosis of asthma, CB, and emphysema</title>
		<link>http://www.diseases-illness.com/diagnosis-of-asthma-cb-and-emphysema.html</link>
		<comments>http://www.diseases-illness.com/diagnosis-of-asthma-cb-and-emphysema.html#comments</comments>
		<pubDate>Thu, 02 Oct 2014 08:02:03 +0000</pubDate>
		<dc:creator><![CDATA[Dan Frost]]></dc:creator>
				<category><![CDATA[Asthma]]></category>
		<category><![CDATA[Diseases]]></category>

		<guid isPermaLink="false">http://www.diseases-illness.com/?p=497</guid>
		<description><![CDATA[In the United States, a more specific criterion was used (GOLD stage IB [ie, FEV1/FVC ratio &#60; 0.7 and FEV1 &#60; 80% predicted]), whereas in Italy a more sensitive criterion (ie, GOLD criterion for stage 1 to 4 disease, without considering FEV1 percent predicted) was used. Indeed, we believe that it is more informative to [&#8230;]]]></description>
				<content:encoded><![CDATA[<p>In the United States, a more specific criterion was used (GOLD stage IB [ie, FEV<sub>1</sub>/FVC ratio &lt; 0.7 and FEV<sub>1</sub> &lt; 80% predicted]), whereas in Italy a more sensitive criterion (ie, GOLD criterion for stage 1 to 4 disease, without considering FEV<sub>1</sub> percent predicted) was used. Indeed, we believe that it is more informative to provide sensitive data to estimate the burden of COPD in the population, in view of the underutilization of spirometry.</p>
<p>The external validity of our study is enhanced by the fact that in our populations the asthma-only group also comprised the largest proportion of OLD patients, and it decreased with increasing age, as in the study by Soriano et al. It is important to point out that our data, like those in <strong>NHANES III</strong>, were collected before or immediately after the publication of the Global Initiative for <strong>Asthma guidelines on asthma</strong>, whereas the UK General Practice Research Viagra Australia Pharmacy Database provided data that were collected several years after. Thus, it would be helpful to perform similar epidemiologic studies in order to assess the possible influence of the updated GOLD guidelines on COPD diagnosis, and of the updated Global Initiative for Asthma guidelines on asthma diagnosis.</p>
<p><em>The fact that the concomitant diagnosis of asthma, CB, and emphysema is common among OLD patients from the general population, particularly in adults aged &gt; 50 years, also has been demonstrated by researchers who have not attempted to develop a proportional Venn diagram.</em> An interesting study on the early detection of COPD or asthma in a random sample from the general population aged 25 to 70 years has been carried out in 10 general practices located in the eastern part of the Netherlands within the framework of the Detection, Intervention, and Monitoring Program of COPD and Asthma program. A total of 19.4% of the general population showed mild objective signs of COPD or asthma. Recently, it has been demonstrated in a cohort of 1,052 subjects with a<sub>1</sub>-antitrypsin deficiency, that asthma was present in 21% of the cohort and attacks of wheezing were reported in 66%.</p>
<p><strong><a href="http://www.myviagrainaustralia.com">www.myviagrainaustralia.com</a> &#8211; treatment with high-quality medications. Always in stock. Large assortment.</strong></p>
]]></content:encoded>
			<wfw:commentRss>http://www.diseases-illness.com/diagnosis-of-asthma-cb-and-emphysema.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Reasons for Diseases: Canadian pharmacy</title>
		<link>http://www.diseases-illness.com/reasons-for-diseases-canadian-pharmacy.html</link>
		<comments>http://www.diseases-illness.com/reasons-for-diseases-canadian-pharmacy.html#comments</comments>
		<pubDate>Wed, 01 Oct 2014 13:45:34 +0000</pubDate>
		<dc:creator><![CDATA[Dan Frost]]></dc:creator>
				<category><![CDATA[Diseases]]></category>

		<guid isPermaLink="false">http://www.diseases-illness.com/?p=495</guid>
		<description><![CDATA[If you all serve love, there will not be ill people. If you have rheumatism, you love is not enough. Each disease is due to an internal insufficiency or to lack of light, or to lack of goodness, or to lack of power. Cheap canadian pharmacy &#8211; all types of medications like viagra, cialis and [&#8230;]]]></description>
				<content:encoded><![CDATA[<p style="text-align: justify;">If you all serve love, there will not be ill people. If you have rheumatism, you love is not enough. Each disease is due to an internal insufficiency or to lack of light, or to lack of goodness, or to lack of power. Cheap canadian pharmacy &#8211; all types of medications like viagra, cialis and kamagra</p>
<p style="text-align: justify;">Human love shall be always cleaned. Otherwise it introduces dirt in the organism. It is a reason for the unclean blood in the organism. To purify human love means to replace it by the Divine one.</p>
<p style="text-align: justify;">You cannot love and be ill. These are two incompatible things. As long as you love, your face cannot be dark, your eyes cannot be blurred. Love bears life.</p>
<p style="text-align: justify;">Phosphorous decreases in the brain, because love has decreased. All elements, which exist at the physical field, are submitted to love, as well as to those elements, of which the spiritual and mental worlds are formed.</p>
<p style="text-align: justify;">When hope in man decreases, diseases come. When faith decreases &#8211; other diseases come. When Love decreases, the worst diseases come. When you increase them, the diseases will go away.</p>
<p style="text-align: justify;">People get ill, because they have broken the law of truth. One, who wants to correct his life and restore his health, he has to come to love the truth.</p>
<p style="text-align: justify;">Pride is the reason for many diseases. All diseases are healed through humility. Man gets free of painful states through humility.</p>
<p style="text-align: justify;">Each physical defect is due to spiritual reasons. If you hate someone, your chests will suffer, a disease will occur there. If you feel envious, your heart will suffer. From envy, jealousy, doubt, suspicion, the liver will suffer. If you indulge yourselves too much in eating, your stomach will get ill. If you get angry, constipation will begin. If you promise and do not fulfill, headache comes. When you find the reason for the illness, balance will be restored, harmony will be established.  at canadianhealthcaremalll.com</p>
<p style="text-align: justify;">When you have a headache, you shall strive to correct your attitude to the Divine world. If you have a chestache, you shall correct your attitude to the spiritual world. If you have a stomachache, you shall correct your attitude to the physical world. Each man&#8217;s disease has its deep reasons, it is not random. Contemporary science and medicine do not look for the internal reasons of things. They consider all phenomena in Nature and life in their internal material side. What is the reason for the stitches at certain parts of the body? They are due to shrinking of the capillaries. It is known that the capillaries serve for the circulation. They bring love to all parts of the body. When the capillaries in the zone of the chest shrink, the electricity in the organism, which bears light, cannot function properly along the entire organism, as a result of which in certain zones more of it accumulates, like the water vapor in a steam-boiler, and causes stitches. Often the atmospheric electricity connects to the electricity of the human organism and a small explosion happens, which is felt as pain by man. What shall you do in order you to get rid of the stitches? Introduce more warmth in your organism. This means to change the state of your feelings and in this way you send more blood to that part of your bodies, in which you feel stitches. When that part gets warm, the stitches go away. Hence, man can cure himself by a strong mind, by strong and positive feelings, as well as by hot water.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.diseases-illness.com/reasons-for-diseases-canadian-pharmacy.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Peyronie’s Disease: Patient Evaluation</title>
		<link>http://www.diseases-illness.com/peyronies-disease-patient-evaluation.html</link>
		<comments>http://www.diseases-illness.com/peyronies-disease-patient-evaluation.html#comments</comments>
		<pubDate>Wed, 27 Aug 2014 13:46:26 +0000</pubDate>
		<dc:creator><![CDATA[Dan Frost]]></dc:creator>
				<category><![CDATA[Diseases]]></category>
		<category><![CDATA[Sexual Health]]></category>
		<category><![CDATA[Canadian pharmacy]]></category>
		<category><![CDATA[generic viagra]]></category>
		<category><![CDATA[New Zealand]]></category>
		<category><![CDATA[Viagra NZ]]></category>

		<guid isPermaLink="false">http://www.diseases-illness.com/?p=456</guid>
		<description><![CDATA[History The evaluation of a man suspected of having PD should begin with a thorough medical his-tory that probes the etiology (e.g., inciting events or trauma), level of disability (i.e., the ability to have intercourse, erectile function, and psychosocial effects), duration of disease, and degree of curvature. Risk factors for severe PD and general medical [&#8230;]]]></description>
				<content:encoded><![CDATA[<h2>History</h2>
<p>The evaluation of a man suspected of having PD should begin with a thorough medical his-tory that probes the etiology (e.g., inciting events or trauma), level of disability (i.e., the ability to have intercourse, erectile function, and psychosocial effects), duration of disease, and degree of curvature. Risk factors for severe PD and general medical concerns should be identified with this evaluation. This data collection can be facilitated by utilizing a disease-specific questionnaire. A patient-supplied photograph of the erect penis can be beneficial in characterizing the degree of deformity, although the measurement of curvature from this image may underestimate the degree of curvature.</p>
<p><strong>Erectile dysfunction can happen in men of any age.</strong> It is especially frustrating when it happens in the young, and it never happens without a reason which might be an underlying physiological or psychological condition. Ailing potency developed at young age should be attended to by multiple specialists and corrected by pills like <a href="http://www.viagra-online.co.nz">Viagra New Zealand</a> and its analogues while the exact diagnosis is being established. With Viagra you will not waste a single fay of the prime of your youth in celibacy!</p>
<h2>Physical Exam</h2>
<p>A directed physical examination is critical to confirm the diagnosis and determine disease severity. The key components of the exam include the genitalia and extremities. Loss of penile length is a common complaint and can worsen over time. Given this, the measurement of stretched penile length provides key information. Plaque characteristics should be noted for their position, size, tenderness to palpation, texture (i.e., calcifications), and number. The hands and feet should be examined for the cord-like thickening of Dupuytren’s contractures or Lederhose’s disease. Other findings may be non-specific; for example, plantar fasciitis is a common complaint in the general population.</p>
<h2>Measurement of Erectile Function and Degree of Curvature</h2>
<p>Several validated questionnaires (SHIM, SEAR, QEQ, etc.) can evaluate erectile function in men with PD. In situations of uncertainty regarding a patient’s erectile function, a cavernosal injection and self stimulation (CIS) test should be performed using vasoactive agents. The CIS test may also provide the most accurate means of measuring penile curvature. A protractor is useful to determine the degree of penile curvature while calipers or a ruler are used to measure penile plaques and nodules.</p>
<h2>Imaging and Vascular Studies</h2>
<p>Ultrasound, X-ray, CT, and MRI have been used to identify abnormalities of the tunica albuginea and corpora cavernosa. Generally, B-mode ultrasound is the most useful technique for measuring the extent of fibrosis or calcification of the tunica albuginea, corpora cavernosa, and septum. Although CT scan, X-rays, and MRI have been used for PD, penile ultrasound identifies calcifica-tions more accurately than these techniques. When vascular abnormalities are suspected, a duplex doppler ultrasound after CIS assesses vascular health and provides the best estimate of penile curvature and deformity. While ultrasound is not used in all centers specializing in the care of men with PD, this relatively low-cost and minimally invasive technique quickly and efficiently identifies the underlying penile abnormality and provides key information that guides medical management and the choice of surgical intervention. From clinical experience, men with extensive calcifications are unlikely to benefit greatly from medical therapy and may require excision of these calcifications to correct the penile curvature.</p>
<h2>Medical and Nonsurgical Therapy</h2>
<p>The current list of medical and nonsurgical treatments for PD is long and reflects the fact that no treatment has been uniformly successful. Few of these treatments with generic viagra online pharmacy have been subjected to rigorous evaluation with randomized trials; however, some therapies have shown consistently positive results. New treatments and nonsurgical interventions are under study that may provide significant benefits for men with PD.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.diseases-illness.com/peyronies-disease-patient-evaluation.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Immunofluorescence assay (IFA)</title>
		<link>http://www.diseases-illness.com/immunofluorescence-assay-ifa.html</link>
		<comments>http://www.diseases-illness.com/immunofluorescence-assay-ifa.html#comments</comments>
		<pubDate>Sat, 26 Jan 2013 22:14:29 +0000</pubDate>
		<dc:creator><![CDATA[Dan Frost]]></dc:creator>
				<category><![CDATA[Diseases]]></category>

		<guid isPermaLink="false">http://www.diseases-illness.com/?p=435</guid>
		<description><![CDATA[PHFAs were cultured on poly-L-lysine-coated 2-chamber glass slides, and the infection was performed as described above. The procedure of immunofluorescence assay has previously been described. Briefly, PHFAs infected with or without HHV-6A were fixed in 4% paraformaldehyde (in PBS), permeabilized in 0.5% Triton X-100 (in PBS), and stained with the anti-gp60/110 monoclonal antibodies (Chemicon international) [&#8230;]]]></description>
				<content:encoded><![CDATA[<p>PHFAs were cultured on poly-L-lysine-coated 2-chamber glass slides, and the infection was performed as described above. The procedure of immunofluorescence assay has previously been described. Briefly, PHFAs infected with or without HHV-6A were fixed in 4% paraformaldehyde (in PBS), permeabilized in 0.5% Triton X-100 (in PBS), and stained with the anti-gp60/110 monoclonal antibodies (Chemicon international) followed by secondary antibody labeled with fluorescein isothiocyanate (FITC).</p>
<p><strong>Electron microscopy</strong></p>
<p>Cells were fixed with 2.5% glutaradehyde at room temperature for 1 h. After washing with PBS, the cells were collected, dehydrated in a series of 70%, 80% and 90% ethanol, and embedded in Epon. Ultrathin sections were cut and mounted in nickel grids, stained with uranyl acetate and lead citrate, and examined by a transmission electron microscopy.</p>
<p><strong>Annexin V-propidium iodide (PI) staining</strong></p>
<p>Apoptosis was measured by Annexin V-propidium iodide (PI) staining and flow cytometry. Infected and uninfected PHFAs were trypsinized, washed in PBS and incubated with Annexin V-FITC and PI solution (Bender MedSystems, Burlingame) in the dark for 15 min. Samples were analyzed by flow cytometry with FACSCalibur and BD CellQuest Pro software (Becton Dickinson, Mountain View). The amount of early apoptosis and late apoptosis was determined as the percentage of Annexin V+/PI- and Annexin V+/PI+, respectively.</p>
<p><strong>Analysis of activated caspase-3 by flow cytometry</strong></p>
<p>Caspase-3 activities in HHV-6A-infected and mock-infected PFHA were tested by flow cytometry with FITC-DEVD-FMK that recognizes cleaved caspase-3 according to the protocol by the manufacturer (Biovision Inc.).</p>
<p><strong>Analysis of caspase-8 and caspase-9 using a colorimetric method</strong></p>
<p>The activation of caspase-8 and caspase-9 was analyzed using a colorimetric assay kit (KeyGEN). Briefly, mock-infected and HHV-6A-infected PFHA were collected and resuspended in 50 μl of lysis buffer and incubated on ice for 30 min. After centrifugation, the protein concentration was assayed by the BCA Protein Assay kit (Byotime), and 50 μg protein was diluted in 50 μl lysis buffer for each assay. Then 5 μl of casepase-8 or caspase-9 substrate were added, respectively. The reaction mixture was incubated at 37°C for 4 h. The released chromphore was measured at 405 nm by a microplate reader.</p>
<p><strong>Preparation of cytosolic and mitochondrial extracts</strong></p>
<p>Cells were washed twice with PBS and kept for 1 h in ice-cold hypotonic buffer (20 mM HEPES, pH7.4, 1.5 mM MgCl2, 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 10 μg/ml leupeptin, aprotinin and pepstatin) containing 250 mM sucrose. The cells were homogenized using a Dounce homogenizer (KONTES), and cytosolic and mitochondrial extracts were isolated as described previously.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.diseases-illness.com/immunofluorescence-assay-ifa.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>HHV-6A activates PARP cleavage and up-regulates bax/bcl-2 ratio. Part 3</title>
		<link>http://www.diseases-illness.com/hhv-6a-activates-parp-cleavage-and-up-regulates-baxbcl-2-ratio-part-3.html</link>
		<comments>http://www.diseases-illness.com/hhv-6a-activates-parp-cleavage-and-up-regulates-baxbcl-2-ratio-part-3.html#comments</comments>
		<pubDate>Thu, 24 Jan 2013 20:50:58 +0000</pubDate>
		<dc:creator><![CDATA[Dan Frost]]></dc:creator>
				<category><![CDATA[Diseases]]></category>

		<guid isPermaLink="false">http://www.diseases-illness.com/?p=431</guid>
		<description><![CDATA[In addition, NF-κB reportedly induces the expression of c-IAP1, c-IAP2 and XIAP, thereby promoting NF-κB activation in a positive feed-back system. NF-κB up-regulation exerts an anti-apoptotic effect leading to cells survival, transformation, and resistance to radiation and drug therapies. In contrast, NF-κB down-regulation will break this feed-back loop and reduce the expression of c-IAP1, c-IAP2 [&#8230;]]]></description>
				<content:encoded><![CDATA[<p><strong>In addition, NF-κB reportedly induces the expression of c-IAP1, c-IAP2 and XIAP, thereby promoting NF-κB activation in a positive feed-back system.</strong> NF-κB up-regulation exerts an anti-apoptotic effect leading to cells survival, transformation, and resistance to radiation and drug therapies. In contrast, NF-κB down-regulation will break this feed-back loop and reduce the expression of c-IAP1, c-IAP2 and XIAP, which are the direct caspase inhibitors. In the present study, we found that HHV-6A decreased NF-κB and increased Iκ-Bα expression in time-dependent manners. IκBα is one member of the family of cellular proteins that function to inhibit the activity of NF-κB. IκBα inhibits NF-κB by masking the nuclear localization signals of NF-κB proteins and keeping them sequestered in an inactive state in the cytoplasm. IκBα up-regulation may inhibit the activity of NF-κB which was observed down-regulation in HHV-6A-infected PHFAs. We also found that HHV-6A decreased expression of c-IAP1, c-IAP2 and XIAP. Increased mitochondrial release of Smac/Diablo could antagonize IAPs expression. Suppression of survival factors such as IAPs and NF-κB could be due to cytosolic up-regulation of Smac/Diablo.</p>
<p><strong>Conclusion</strong></p>
<p>We demonstrated that HHV-6A induces cell apoptosis in PHFAs through both caspase-dependent and -independent apoptosis pathways, as evidenced by (1) activation of caspase-3, -8 and -9; (2) increasing the ratio of Bax/Bcl-2; (3) increasing the presence of Smac/Diablo, AIF and cytochrome c in cytoplasm; (4) down-regulation of anti-apoptotic NF-κB and IAPs. The identification of the apoptotic signaling pathways in HHV-6A-infected PHFAs would be very helpful in understanding the mechanisms by which HHV-6A infection causes diseases in the CNS.</p>
<p><strong>Materials and methods</strong><br />
Cells and viruses</p>
<p>The primary human fetal astrocytes (Sciencell) were cultured in DEME/F12 (Hyclone) supplemented with 10% fetal calf serum, 100 IU/ml penicillin/streptomycin (Invitrogen). Human T-cell line HSB-2 cells were cultured in RPMI 1640 medium containing 8% fetal calf serum. HHV-6A strain GS was inoculated into HSB-2 cells. The cells were frozen and thawed twice when 80% of HHV-6A-infected HSB-2 cells showed the cytopathic effects (CPE), then centrifuged at 2000 × g for 10 min. The supernatants were stored at -70°C as cell-free virus. Viral DNA equivalents of the frozen aliquot were tested by quantitative PCR. Uninfected HSB-2 cells were similarly cultured and treated using the same procedure and used for mock infection. For infection, 3 × 105 primary human fetal astrocytes (PHFAs) were seeded onto a poly-L-lysine (Sigma)-coated 25-cm2 flask (Corning). After an overnight incubation, the plate was washed three times with phosphate-buffered saline (PBS) and infected with cell-free supernatant containing 108 viral DNA copies/106 PHFAs. After 3 h incubation at 37°C in 5% CO2, cultures were washed three times with PBS, and fresh medium was added. The HHV-6A-infected cells were checked for CPE every day in microscopy. Procedures for mock infection were performed in the same manner as for viral infection.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.diseases-illness.com/hhv-6a-activates-parp-cleavage-and-up-regulates-baxbcl-2-ratio-part-3.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>HHV-6A activates PARP cleavage and up-regulates bax/bcl-2 ratio. Part 2</title>
		<link>http://www.diseases-illness.com/hhv-6a-activates-parp-cleavage-and-up-regulates-baxbcl-2-ratio-part-2.html</link>
		<comments>http://www.diseases-illness.com/hhv-6a-activates-parp-cleavage-and-up-regulates-baxbcl-2-ratio-part-2.html#comments</comments>
		<pubDate>Thu, 17 Jan 2013 16:33:16 +0000</pubDate>
		<dc:creator><![CDATA[Dan Frost]]></dc:creator>
				<category><![CDATA[Diseases]]></category>

		<guid isPermaLink="false">http://www.diseases-illness.com/?p=429</guid>
		<description><![CDATA[HHV-6 was first isolated from peripheral blood mononuclear cells of patients with lymphoproliferative disorders and AIDS. There are two variants of HHV-6 (A and B) according to distinct genetic, immunological and virological characteristics. As with other virus, HHV-6 is able to induce apoptosis of host cells. Subsequent studies have demonstrated that HHV-6 has been shown [&#8230;]]]></description>
				<content:encoded><![CDATA[<p><strong>HHV-6 was first isolated from peripheral blood mononuclear cells of patients with lymphoproliferative disorders and AIDS.</strong> There are two variants of HHV-6 (A and B) according to distinct genetic, immunological and virological characteristics. As with other virus, HHV-6 is able to induce apoptosis of host cells. Subsequent studies have demonstrated that HHV-6 has been shown to induce apoptosis in astrocytes, oligodendrocytes, neuronal cell lines and CD4+ T lymphocytes. Gardell et al. reported that HHV-6A induced apoptosis by an unknown mechanism in astrocytes, oligodendrocytes and neuronal cell lines. Inoue et al. demonstrated that TNF-α and anti-Fas antibodies augmented HHV-6-induced apoptosis, suggesting an involvement bof death receptors in HHV-6-induced apoptosis. In contrast, Inchimi et al. found that HHV-6 induced apoptosis of cord blood lymphocytes through a receptor-independent pathway. </p>
<p>Caspases play a critical role in apoptosis, which cleave specific substrates and activate downstream molecules and culminate in cell death. However, the roles of caspases in HHV-6-induced apoptosis of astrocytes haven&#8217;t been studied yet. In this study, we demonstrated that the activities of caspase-3, -8 and -9 were all increased in HHV-6A-induced apoptosis of PHFAs. In addition, we found that PARP was cleaved in HHV-6A-induced apoptotic PHFAs. Caspase-3 is a common effector of both death receptor and the mitochondrial signaling pathways. Caspase-8 is activated by the death receptor signaling pathway, whereas caspase-9 is activated in the mitochondrial signaling pathway during apoptosis. We speculate that HHV-6A-induced apoptosis in astrocytes via both caspase-dependent receptor and mitochondrial apoptotic pathways. </p>
<p><em>Bcl-2 family proteins are central regulators of the mitochondrial apoptotic pathway and have been implicated in various models of virus-induced apoptosis.</em> Pugazhenthi et al. found that simian varicella virus induced apoptosis in monkey kidney cells via caspase-dependent mitochondrial pathway and involves down-regulation of bcl-2 expression. The translocation and accumulation of Bax, a pro-apoptotic factor of Bcl-2 family in mitochondria will lead to release of cytochrome c and AIF. We examined the expression of Bcl-2 and Bax in HHV-6A-induced mitochondrial dysfunction. Our data showed that the anti-apoptotic protein Bcl-2 decreased, which was accompanied by the increase of pro-apoptotic protein Bax during HHV-6A infection, suggesting that Bcl-2 and Bax were involved in the apoptosis of HHV-6A-infected PHFAs. </p>
<p>Up-regulation of Bax induces the permeabilization of mitochondrial outer membrane and initiates mitochondrial dysfunction. Mitochondria may release several molecules including cytochrome c, Smac/Diablo, and AIF to induce apoptosis via the caspase-dependent and -independent pathways [24-26]. We separated the cytosolic and mitochondrial fractions to examine the cytochrome c levels by Western blotting and found a marked increase in cytochrome c level in the cytosolic fraction due to a concomitant decrease in the cytochrome c level in the mitochondrial fraction following HHV-6A infection. Mitochondrial cytochrome c releases into cytoplasm to bind to the apoptosis protease activation factor (APAF1) and to form a complex of apoptosome activating pro-caspase 9. The activation of pro-caspase 9 initiates an enzymatic reaction cascade leading to the execution of apoptosis in cells. We also observed a time-dependent increase the cytosolic level of Smac/Diablo following infection compared with control cells. Smac/Diablo can inhibit inhibitor-of-apoptosis-proteins (IAPs), which otherwise inactivate caspases. Mitochondria-mediated apoptosis may also occur caspase-independently after mitochondrial release of AIF and Endo G which are translocated to the nucleus for induction of chromatin condensation and DNA fragmentation. Our investigation demonstrated that HHV-6A markedly increased the cytosolic level of AIF in PHFAs, indicating involvement of caspase-independent pathway of apoptosis.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.diseases-illness.com/hhv-6a-activates-parp-cleavage-and-up-regulates-baxbcl-2-ratio-part-2.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>HHV-6A activates PARP cleavage and up-regulates bax/bcl-2 ratio</title>
		<link>http://www.diseases-illness.com/hhv-6a-activates-parp-cleavage-and-up-regulates-baxbcl-2-ratio.html</link>
		<comments>http://www.diseases-illness.com/hhv-6a-activates-parp-cleavage-and-up-regulates-baxbcl-2-ratio.html#comments</comments>
		<pubDate>Sat, 12 Jan 2013 13:45:24 +0000</pubDate>
		<dc:creator><![CDATA[Dan Frost]]></dc:creator>
				<category><![CDATA[Diseases]]></category>

		<guid isPermaLink="false">http://www.diseases-illness.com/?p=427</guid>
		<description><![CDATA[PARP is an established substrate for caspase-3 in the apoptotic events. Cleavage of PARP facilitates cellular disassembly and serves as a marker of cells undergoing apoptosis. Western blotting was used to detect endogenous full-length PARP (116 KD), as well as the large fragment (89 KD) of PARP resulting from caspase cleavage. As shown in Figure [&#8230;]]]></description>
				<content:encoded><![CDATA[<p>PARP is an established substrate for caspase-3 in the apoptotic events. Cleavage of PARP facilitates cellular disassembly and serves as a marker of cells undergoing apoptosis. Western blotting was used to detect endogenous full-length PARP (116 KD), as well as the large fragment (89 KD) of PARP resulting from caspase cleavage. As shown in Figure 4a, the 89 KD cleaved fragment of PARP was detected in infected cells at 48 and 72 hpi, but not detected in the mock-infected cells.</p>
<p>The mitochondria-mediated pathway of apoptosis is regulated by the Bcl-2 family proteins, which are known to directly regulate mitochondrial membrane permeability. We examined the levels of expression of Bax (pro-apoptotic) and Bcl-2 (anti-apoptotic) proteins using Western blotting analysis. As shown in Figure 4b, the levels of Bcl-2 protein were significantly decreased following HHV-6A infection compared to that in mock-infected cells, whereas the expression of Bax protein was significantly increased in HHV-6A-infected cells. These results indicate Bax/Bcl-2 ratio was significantly increased in HHV-6A-infected cells compared with mock-infected cells.</p>
<p><strong>HHV-6A infection results in the release of pro-apoptotic proteins from mitochondria</strong></p>
<p>Mitochondria may release several molecules including cytochrome c, Smac/Diablo, and AIF to induce apoptosis. Mitochondrial cytochrome c release is a well-known pre-condition for formation of apoptosome and activation of caspases for apoptosis. There is a marked increase in the levels of cytochrome c released from mitochondria to cytoplasm at 48 and 72 hpi compared with control. Smac/Diablo plays an important role in apoptosis by down-regulation anti-apoptotic IAPs. The expression levels of Smac/Diablo were significantly increased following HHV-6A infection in a time-dependent manner compared to that in mock-infected cells. In addition, the expression levels of AIF, determining caspase-independent pathway of apoptosis were also increased obviously in HHV-6A infected cells compared to that in mock-infected cells. The results suggest that HHV-6A infection in PHFAs can provoke apoptosis via the mitochondrial intrinsic pathway.</p>
<p><strong>HHV-6A suppresses IAPs and NF-κB-mediated anti-apoptosis effect</strong></p>
<p>IAPs are thought to function primarily by negative regulation caspases, which are cysteine proteases involved in apoptosis. In human cells, IAPs mainly include cIAP1, cIAP2 and XIAP. As shown in Figure 6, the levels of these three IAPs were significantly decreased in the HHV-6A-infected cells compared to those in mock-infected cells.</p>
<p>NF-κB plays a crucial role not only in immunity, inflammation and cell migration but also in cell survival and apoptosis. Many studies confirmed that NF-κB up-regulation and activation exerted an anti-apoptotic effect leading to cells survival, transformation, and resistance to radiation and chemotherapy. The levels of NF-κB were significantly decreased in HHV-6A-infected cells compared to that in mock-infected cells, while the expression of NF-κB inhibitor-IκBα protein was significantly increased in HHV-6A-infected cells. These results indicate that HHV-6A infection injures IAPs and NF-κB-mediated anti-apoptosis signal pathways in PHFAs.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.diseases-illness.com/hhv-6a-activates-parp-cleavage-and-up-regulates-baxbcl-2-ratio.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>HHV-6A causes productive infection in PHFAs</title>
		<link>http://www.diseases-illness.com/hhv-6a-causes-productive-infection-in-phfas.html</link>
		<comments>http://www.diseases-illness.com/hhv-6a-causes-productive-infection-in-phfas.html#comments</comments>
		<pubDate>Thu, 10 Jan 2013 14:49:32 +0000</pubDate>
		<dc:creator><![CDATA[Dan Frost]]></dc:creator>
				<category><![CDATA[Diseases]]></category>

		<guid isPermaLink="false">http://www.diseases-illness.com/?p=425</guid>
		<description><![CDATA[HHV-6A was used to infect PHFAs at comparable levels of virus DNA (1 × 108 copies/106 cells) as determined by quantitative PCR. HHV-6A-infected PHFAs showed typical cytopathic effects (CPE) such as cellular swelling and cell fusion at 72 h post-infection (hpi). To further determine HHV-6A infection in PHFAs, the expression of a late protein gp60/110 [&#8230;]]]></description>
				<content:encoded><![CDATA[<p><em>HHV-6A was used to infect PHFAs at comparable levels of virus DNA (1 × 108 copies/106 cells) as determined by quantitative PCR.</em> HHV-6A-infected PHFAs showed typical cytopathic effects (CPE) such as cellular swelling and cell fusion at 72 h post-infection (hpi). To further determine HHV-6A infection in PHFAs, the expression of a late protein gp60/110 was analyzed using immunofluorescence assay and western blotting at 72 hpi. As shown in Figure 1b, a prominent expression of HHV-6 gp60/110 was detected in HHV-6A-infected PHFAs compared with that in the control mock-infected cells. The gp60/110 late protein was clearly localized in the cytoplasm of most multinucleate giant cells. Electron microscopic analyses were also performed on HHV-6A-infected PHFAs at 72 hpi. As shown in Figure 1c, viral particles could be visualized in both cytoplasm and extracellular matrix of HHV-6A-infected PHFAs. These results indicate that HHV-6A can cause productive infection in PHFAs.</p>
<p><strong>HHV-6A induces apoptosis of PHFAs</strong></p>
<p>To investigate the effect of HHV-6A infection on apoptosis in PHFAs, cells infected with HHV-6A were stained with annexin-V-FITC and propidium iodide (PI) after 24, 48, and 72 hpi and analyzed by flow cytometry. As shown in Figure 2a, we observed a high percentage of annexin-positive cells (apoptotic cells) in HHV-6A-infected cells at 72 hpi compared to mock-infected cells. The percentage of early apoptotic cells and late apoptotic cells at 72 hpi reached 5.89% and 17.5% compared to 0.64% and 2.48% in mock-infected cells, respectively. To further confirm the effect of HHV-6A on cell apoptosis, we also observed the morphologic changes in HHV-6A-infected cells using transmission electron microscopy. HHV-6A-infected PHFAs showed the typical features of cell apoptosis: marginalized and condensed chromatin matrix, shrinkage and blebbing of the cytoplasm and fragmented nuclei. Virus-like particles could be found in apoptotic HHV-6A-infected PHFAs.</p>
<p><strong>HHV-6A triggers caspases activation</strong></p>
<p>Caspases are synthesized as inactive precursors that are processed to large and small subunits to form the active enzymes. Caspase-3 is one of the main effective caspases, which are activated in response to both intracellular and extracellular death signals. To explore the pathway by which HHV-6A induced apoptosis, we measured caspase-3 activity in HHV-6A-infected PHFAs with anti-active caspase-3 antibody using flow cytometry. PHFAs with activated caspase-3 were about 2.81%, 10.12% and 19.31% at 24, 48 and 72 hpi, respectively, whereas the value was only 0.69% in the mock-infected cells. To further define whether HHV-6A induces apoptosis via the receptor-mediated or the mitochondria-mediated pathways, the activities of caspase-8 and -9 were measured, respectively. HHV-6A infection resulted in significant increases in caspase-8 and caspase-9 activities at 48 and 72 hpi in HHV-6A-infected cells compared with mock-infected cells. These data indicate that HHV-6A induce apoptosis of PHFAs by both the receptor-mediated and the mitochondria-mediated pathways.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.diseases-illness.com/hhv-6a-causes-productive-infection-in-phfas.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
